A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Twice a Week in Adult Patients With Advanced Solid Malignancies Including Lymphoma.

Trial Profile

A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Twice a Week in Adult Patients With Advanced Solid Malignancies Including Lymphoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2009

At a glance

  • Drugs AZD 4877 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Sep 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 22 Jul 2008 The expected completion date for this trial is now 1 Nov 2009, from clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top